中国药业研发国际峰会 China Pharmaceutical R&D Summit 2011
地点：上海金茂君悦大酒店
主办单位： IBC Asia (S) Pte Ltd
China''''s Premier Life Science event will be coming back to Shanghai for the 6th year with a completely NEW FORMAT and NEW CONTENT!
China Pharmaceutical R&D Summit is the longest standing event in China.
View the event archives to see the outstanding track record this conference has and the past conference highlights.
The 2011 Event... 3 Focused Conferences: View the Agenda-at-a-Glance (PDF)
Clinical & Regulatory Summit
- Understand the Regulatory Environment in China
- Hear from a tuned-in Clinical CRO on the changing regulatory environment; a US company''''''''s insight on conducting global trials in Asia, and a leading consultant''''s strategy to bring Chinese drugs and biologics to US market.
- Benefit from these Tried & Proven Clinical Strategies and Case Studies:
- FIH Study in China: from IND Application to Study Completion
- Getting Ready for Global Trials in China
- Conducting Health Economics & Outcomes Research in China
- Developing Risk Management Plan in Clinical Trials
- Bridging China Data with Global Data - Global Simultaneous Development
- Trials & Tribulations of Starting Clinical Trials in a New Geographic Region
Discovery to Preclinical Development & Partnerships
- Hear the Latest in NCE Development from these Domestic Chinese Companies:
- Hec Pharma, Ascentage Pharma, IMPACT Therapeutics, Sunwei Therapeutics, Argusina Shanghai, Nanjing Changao Pharmaceutical, Luye Pharma Group and TOT Shanghai
- Get Exciting Partnering Strategies and Updates from:
- Roche, Simcere Pharmaceuticals, Pfizer, AstraZeneca, Fosun Pharmaceutical, Synta Pharmaceuticals, DCB Taiwan, GSK and Eli Lilly
Biologics & Biosimilars Development
- Hear Rarely-Told Stories of China''''s Biologics Development:
- History of Licartin - a I-131 Labeled Anti-CD147 Launched in China for Liver Cancer
- EGFR mAb - a 10-Year Development Effort
- A 10-year Development History of Etanercept in China
- TPO - an Innovative Biopharmaceutical Product in China
- Interleukin-7 Receptor: A New Therapeutic Target Using Biological Approach
- Developing Oral Insulin in China - Experiences and Lessons
- Learn from Success Stories of Large Molecule Development from Around the World:
- Alternatives to Antibodies - High Affinity Mirror-Image Oligonucleotides
- Story of Abgenix: from XenoMouse to Panitumumab and Beyond
- Development of Cell Therapy in China
- Peptide Therapeutics in China
A never-before line-up of over 75 Speakers from international pharma, MNCs in China, and domestic Chinese pharma/biotechs will be sharing their expert opinions and experiences on clinical challenges, regulatory updates , NCE discovery efforts, preclinical partnerships, biosimilars development and more!
With shared Keynote and Plenary Sessions over 3 days, participants will be able to choose the conference of their choice or mix-and-match sessions from all 3 conferences, while taking advantage of the shared sessions and networking breaks to meet with other executives and scientists at the event.
With proven attendance from top-level executives from China''''''''s major pharma and biotech companies, this is THE MEETING PLACE to network and share experiences, meet potential partners and foster business relationships.
临床及法律规范高峰会
- 理解中国的法律规范环境
- 关于法律规范环境的变化、可以听取到最前线临床CRO的内容。美国企业对于在亚洲所实施的临床试验之见解、第一线顾问的中国医药品、生物制剂在美国市场所带来的策略等。
- 学习所实行、确立的临床策略及个案研究
- 中国的FIH研究：临床实验药的应用到研究完成
- 中国的全球临床实验准备态势
- 中国的医疗经济学和效果研究实施
- 临床试验的风险管理计划决定
- 中国的数据和国际的数据之间差距的解决 － 全球同时开发
- 新地区展开临床试验的实行和考验
从创药到前临床开发、及合作
- 中国国内企业的NCE开发最新趋势
- Hec Pharma, Ascentage Pharma, IMPACT Therapeutics, Sunwei Therapeutics, Argusina Shanghai, Nanjing Changao Pharmaceutical, Luye Pharma Group and TOT Shanghai
- 以下企业的合作策略和最新趋势
- Roche, Simcere Pharmaceuticals, Pfizer, AstraZeneca, Fosun Pharmaceutical, Synta Pharmaceuticals, DCB Taiwan, GSK and Eli Lilly
生物制剂和生物学名药开发
- 难能可贵的中国生物制剂开发趋势的解说
- Licartin的历史 － 因肝癌在中国所上市的a I-131抗CD147抗体标志
- EGFR mAb - 10年开发的计划
- 中国的Etanercept 10年的开发历史
- TPO ― 中国的革新生物医药品
- Interleukin7受体：使用生物学方案的新治疗标的
- 中国的口服胰岛素开发 － 经验和教训
- 学习全球中大型分子开发的成功案例
- 抗体替代物 － 高亲和性镜像寡核酸
- Abgenix的物语：XenoMouse到Panitumumab
- 中国细胞疗法的发展
- 中国的缩氨酸疗法
聚集全球医药品业界超过75位的演讲者、中国国内的制药公司、生物科技公司对临床实验的相关课题及法律规范的最新趋势、NCE创药的计划、前临床阶段的合作、生物学名药开发等、独自的专门见解及体验的意见交换。
为期3天的基础演讲及总会、参加者可由3个会议中选出最适合的会议、或是组合喜好的会议参加。此外可透过共通会议及网路与其他机构的干部及科学家们进行交流。
中国的大型制药公司及生物科技企业的最高干部们也会参与本会议。期待您能莅临会场、给予意见交换及和未来的合作对象面谈、能有助于商业关系的架构。
